ClinicalTrials.gov
public full text
Public Domain
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia#1112412
- Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort#1157670
- Pharmacological management in frontotemporal dementia and patient outcomes: a retrospective cohort study using the TriNetX platform.#1000970
- Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia#1033547
- Granulin loss and TMEM106B risk converge on lysosomal C-terminal fragment pathology in frontotemporal dementia#135531
Record · ID 810337
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive